The Wolverine Stack: BPC-157 + TB-500 Research Guide
A research-framed look at the BPC-157 and TB-500 pairing, what each peptide is studied for, why researchers investigate them together, and the lab-verified kit. Strictly research use only.
What is the Wolverine stack?
The Wolverine stack is a community nickname for the pairing of two research peptides, BPC-157 and TB-500. It is not a clinical designation, a brand name, or a recognised therapeutic protocol. The name was borrowed from the comic-book character known for rapid healing, and it spread informally among researchers and online communities. The kit described on this page combines BPC-157 5mg and TB-500 5mg as a single 10mg total blend, supplied strictly for laboratory research use.
The Wolverine stack is an informal nickname for BPC-157 paired with TB-500. The kit referenced here is a 5mg + 5mg (10mg total) blend. The two peptides are studied in preclinical models for complementary, non-overlapping mechanisms, which is the reason researchers investigate them together. Neither compound is approved for human use anywhere, and both are research use only.
It is worth clearing up one common point of confusion. Some market listings reference a 10mg + 10mg (20mg total) blend, but the kit described on this page is specifically the 5mg + 5mg composition. Throughout this guide we describe only that 10mg total kit, and we keep every statement framed as what each peptide is studied or investigated for, never as a claimed outcome.
What BPC-157 is studied for
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide sequence partial to a protective protein originally identified in human gastric juice. It is a laboratory compound, studied in vitro and in animal models, and it is not the natural protein itself.
In preclinical research literature, BPC-157 is investigated in connection with several pathways. These are areas of scientific study, not demonstrated human effects.
- Angiogenesis, the formation of new blood vessels, associated in the literature with VEGF and VEGFR2 signalling pathways
- Fibroblast activity and collagen-related repair pathways
- The tendon-bone interface and structural tissue research models
- Gastrointestinal and gastric tissue protection in animal studies
One characteristic that comparative research literature emphasises is that BPC-157 is described as acting more locally, near the site of administration, through localised structural and growth-factor signalling. That local profile is the key contrast point that sets up the pairing rationale below. For a deeper standalone treatment of the chemistry and the research record, see the dedicated BPC-157 research guide.
What TB-500 is studied for
TB-500 is a synthetic 17-amino-acid peptide fragment of Thymosin Beta-4 (TB4). It contains the central actin-binding motif LKKTETQ. It is accurately described as a fragment or analogue of thymosin beta-4, not as thymosin beta-4 itself, and like BPC-157 it is studied in laboratory and animal models only.
The primary mechanism investigated for TB-500 in research is G-actin sequestration and regulation of the actin cytoskeleton, in other words modulating the balance between G-actin and F-actin. This is studied in connection with cell migration. In the literature TB-500 is associated with the migration of endothelial cells, keratinocytes, fibroblasts and stem or progenitor cells, and it appears in angiogenesis and tissue-repair research models.
The contrast that matters for the stack is direction of action. Comparative research literature characterises TB-500 as acting more systemically, travelling via the circulation and supporting cell migration across multiple tissues, rather than concentrating its activity at a single local site. The standalone TB-500 research guide covers this mechanism and the surrounding research in more detail.
Why researchers pair BPC-157 and TB-500
The scientific rationale researchers cite for studying the two together is complementarity, not synergy in the marketing sense. The two peptides are investigated for different, non-redundant mechanisms. TB-500 is studied for systemic cell-migration and cell-mobilisation effects across tissues, while BPC-157 is studied for more localised angiogenic and growth-factor signalling at a specific site.
BPC-157 is characterised in the literature as acting more locally near a site, while TB-500 is characterised as acting more systemically via the circulation. This local-versus-systemic contrast is the core reason researchers investigate the two peptides side by side. It explains why they are studied together, but it is not evidence that the combination produces any particular result.
Framed honestly, this is why the pairing is investigated together, not a guarantee of a combined outcome. If you want to see the two mechanisms placed directly side by side, the BPC-157 vs TB-500 comparison page breaks down the local-versus-systemic distinction in full.
The state of the evidence
Honesty about the research record matters. Most existing evidence for both BPC-157 and TB-500 comes from in vitro and animal (preclinical) studies. Human clinical evidence is limited. Anyone evaluating this topic should treat the two compounds as research subjects rather than as established interventions, and should be cautious of any source that presents preclinical findings as proven human benefits.
For that reason, this page deliberately avoids outcome claims, study-count figures and percentages. We describe what each peptide is studied for and why the pairing is investigated, and we leave the interpretation of the underlying literature to the researcher.
Australian and sporting status
Both compounds carry important regulatory context in Australia that researchers should understand before sourcing or handling them. None of the following is legal or medical advice; it is factual context.
- BPC-157 was placed in Schedule 4 (Prescription Only Medicine) of the Poisons Standard and added to Appendix D, effective 1 June 2024.
- BPC-157 is on the WADA Prohibited List under category S0 (Non-Approved Substances), prohibited at all times in sport, and is not eligible for a Therapeutic Use Exemption. Sport Integrity Australia publishes substance education consistent with this.
- TB-500 and thymosin beta-4 derivatives are also prohibited in sport under the WADA Prohibited List (S0, prohibited at all times).
- Neither BPC-157 nor TB-500 is approved for human therapeutic use by the TGA, the FDA or the EMA. Both are positioned strictly as research-use-only compounds.
In short, these are unapproved research compounds, not medicines, and the sporting bodies treat them as prohibited at all times. Treat them accordingly.
The kit and the Janoshik COA
NovaPeptides supplies the Wolverine stack as a complete research kit: BPC-157 5mg and TB-500 5mg as a 10mg total blend, with independent third-party lab verification and Australian shipping. The point of difference is verifiable proof of identity and purity rather than a claim you have to take on trust.
Janoshik Analytical is an independent, third-party analytical chemistry laboratory based in the Czech Republic that is widely used across the research-peptide industry for purity and identity verification. Janoshik testing typically combines two methods. High-Performance Liquid Chromatography (HPLC) produces the purity figure and a chromatogram, while Mass Spectrometry (MS) confirms that the dominant peak is the correct molecule, which is the identity confirmation.
Janoshik assigns each tested batch a unique reference printed on the official Certificate of Analysis, and the reports are hosted on Janoshik's own servers. That means a researcher can verify a report directly with the lab using the batch reference, without involving the vendor. We encourage you to confirm the report and read the actual reported purity and identity figures from the COA itself.
We deliberately do not publish a purity percentage in this guide. The honest approach is for the figure to come from the verified Janoshik report rather than from marketing copy, so check the COA directly. Enquiries about the kit are handled by WhatsApp; there is no cart or price on this page.
Frequently asked questions
Is the Wolverine stack an approved treatment?+
No. The Wolverine stack is an informal community nickname for BPC-157 paired with TB-500. It is not a clinical protocol, a brand name or an approved treatment. Neither peptide is approved for human use by the TGA, FDA or EMA, and both are supplied strictly for research use only.
How much BPC-157 and TB-500 is in this kit?+
The kit described here is a 10mg total blend made up of BPC-157 5mg and TB-500 5mg. Some other market listings reference a larger 10mg + 10mg (20mg) blend, but this guide describes only the 5mg + 5mg composition of the kit referenced here.
Why do researchers study BPC-157 and TB-500 together?+
Because the two are investigated for complementary, non-redundant mechanisms. Research literature characterises BPC-157 as acting more locally near a site through angiogenic and growth-factor signalling, while TB-500 is characterised as acting more systemically via the circulation in connection with cell migration. That local-versus-systemic contrast is the rationale for studying them together. It is not evidence of a combined outcome.
What is the difference between TB-500 and thymosin beta-4?+
TB-500 is a synthetic 17-amino-acid fragment of thymosin beta-4 that contains the central actin-binding motif LKKTETQ. It is a fragment or analogue, not the full thymosin beta-4 protein itself.
Is BPC-157 legal in Australia?+
BPC-157 was placed in Schedule 4 (Prescription Only Medicine) and added to Appendix D of the Poisons Standard, effective 1 June 2024. It is also on the WADA Prohibited List under S0 and is prohibited at all times in sport. This is factual context, not legal advice, and the compound is supplied for research use only.
How can I verify the Janoshik COA?+
Janoshik assigns each tested batch a unique reference printed on the Certificate of Analysis, and reports are hosted on Janoshik's own servers. You can confirm the report directly with the lab using the batch reference, independent of the vendor. We recommend reading the actual purity and identity figures straight from the verified report.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp